Annette Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Annette Thomas has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Danielle Freedman
Clinical Biochemistry, Luton & Dunstable University Hospital NHS Foundation Trust (Bedfordshire Hospitals NHS Foundation Trust), Luton, UK
3 shared publications- David Housley
Clinical Biochemistry, Luton & Dunstable University Hospital NHS Foundation Trust (Bedfordshire Hospitals NHS Foundation Trust), Luton, UK
3 shared publications - Finlay MacKenzie
Birmingham Quality (UK NEQAS) , 1732 University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK
3 shared publications - Martin Myers
GIRFT Pathology, NHS England, London, UK
3 shared publications - Rachel Marrington
Birmingham Quality (UK NEQAS) , 1732 University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK
3 shared publications Gareth Davies
Weqas, Cardiff and Vale University Health Board , Cardiff , UK
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Becaris Publishing Limited in Journal of Patient Centricity
- Vol. 1 (2)
The Yellow Card Scheme for laboratory medicine in vitro diagnostics
Background: The Yellow Card Scheme was introduced in the UK in 1964 with an aim to address adverse drug reactions patient safety concerns. Medical devices are now included within the scope of reportable events. Aim: We report here what we believe is the first survey of the Yellow Card Scheme in relation to medical devices in the clinical laboratory. Materials & methods: A Microsoft Forms descriptive, cross-sectional survey was made available by the Patient Focused Laboratory Medicine Group to anyone working within the discipline of laboratory medicine in the UK; however, dissemination was limited through primarily clinical biochemistry channels. The survey was open for 32 days. Questions were structured that respondents could only continue, firstly if they were aware of the Yellow Card Scheme and a secondly, if they had ever made a submission. We know from external quality assessment post-market surveillance that over the last year there have been multiple assays with significant changes in analytical performance to cause a change in patient management, therefore it would be expected that a notable number of Yellow Cards should be reported. Results: Responses were received from 321 individuals. Out of the 207 respondents who were aware of the Yellow Card Scheme, 140 (68%) have not raised a Yellow Card. Of the Yellow Cards that had been raised, only 23% of respondents who have raised a Yellow Card use the Scheme regularly, this equates to only 5% of the total respondents to the survey. Free text comments were allowed to some questions, a few responses are included in full in the paper, some of which are alarming. Conclusion: Lack of awareness of the overall process shows that there is an educational issue and concerns about completion of the form, lack of feedback and consequential disengagement with the process potentially means it is not fit for purpose, which could explain why people are not using it. We believe that this is a potentially huge patient safety issue.
- 1 October 2026
- Published by Becaris Publishing Limited in Journal of Patient Centricity
- Vol. 1 (2)
Open AccessThe Yellow Card Scheme for laboratory medicine in vitro diagnostics
Background: The Yellow Card Scheme was introduced in the UK in 1964 with an aim to address adverse drug reactions patient safety concerns. Medical devices are now included within the scope of reportable events. Aim: We report here what we believe is the first survey of the Yellow Card Scheme in relation to medical devices in the clinical laboratory. Materials & methods: A Microsoft Forms descriptive, cross-sectional survey was made available by the Patient Focused Laboratory Medicine Group to anyone working within the discipline of laboratory medicine in the UK; however, dissemination was limited through primarily clinical biochemistry channels. The survey was open for 32 days. Questions were structured that respondents could only continue, firstly if they were aware of the Yellow Card Scheme and a secondly, if they had ever made a submission. We know from external quality assessment post-market surveillance that over the last year there have been multiple assays with significant changes in analytical performance to cause a change in patient management, therefore it would be expected that a notable number of Yellow Cards should be reported. Results: Responses were received from 321 individuals. Out of the 207 respondents who were aware of the Yellow Card Scheme, 140 (68%) have not raised a Yellow Card. Of the Yellow Cards that had been raised, only 23% of respondents who have raised a Yellow Card use the Scheme regularly, this equates to only 5% of the total respondents to the survey. Free text comments were allowed to some questions, a few responses are included in full in the paper, some of which are alarming. Conclusion: Lack of awareness of the overall process shows that there is an educational issue and concerns about completion of the form, lack of feedback and consequential disengagement with the process potentially means it is not fit for purpose, which could explain why people are not using it. We believe that this is a potentially huge patient safety issue.
- 14 August 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Two CCLM papers: different routes, common goals
- 14 August 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Two CCLM papers: different routes, common goals
- Open Access
- 12 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (10) , 2159-2167
Clinical quality in UK laboratory medicine: current status and what the wider laboratory community can learn
In the UK, in 2024, variation in the performance of the HbA1c assay resulted in the misdiagnosis of patients. This was well publicised in the media, and over 55,000 patients (in England) needed to be recalled for repeat testing, and many patients had their diagnosis changed. However, during the investigation into this event, it became clear that the Clinical Quality Infrastructure for laboratory medicine in the UK requires review. The importance of such an infrastructure was first proposed in the Barnes Report into how diagnostic variation resulted in misdiagnosis of patients. During our review into the recent event, it became clear that little of the Ian Barnes recommendations have been translated into practice, and we discovered further ‘gaps’ in the laboratory medicine Quality Infrastructure that could be applicable to the wider laboratory community. This article will not focus specifically on the HbA1c incident but will use HbA1c as an example of what we have used for a springboard for change and gives an overview of key areas that clinical laboratories should be considering as part of their risk management for the services provided for patient care. A number of recommendations have been made for UK laboratories endorsed by GIRFT (Getting It Right First Time), Birmingham Quality (member of the UK NEQAS consortium) and Weqas.
- 12 June 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (10) , 2159-2167
Open AccessClinical quality in UK laboratory medicine: current status and what the wider laboratory community can learn
In the UK, in 2024, variation in the performance of the HbA1c assay resulted in the misdiagnosis of patients. This was well publicised in the media, and over 55,000 patients (in England) needed to be recalled for repeat testing, and many patients had their diagnosis changed. However, during the investigation into this event, it became clear that the Clinical Quality Infrastructure for laboratory medicine in the UK requires review. The importance of such an infrastructure was first proposed in the Barnes Report into how diagnostic variation resulted in misdiagnosis of patients. During our review into the recent event, it became clear that little of the Ian Barnes recommendations have been translated into practice, and we discovered further ‘gaps’ in the laboratory medicine Quality Infrastructure that could be applicable to the wider laboratory community. This article will not focus specifically on the HbA1c incident but will use HbA1c as an example of what we have used for a springboard for change and gives an overview of key areas that clinical laboratories should be considering as part of their risk management for the services provided for patient care. A number of recommendations have been made for UK laboratories endorsed by GIRFT (Getting It Right First Time), Birmingham Quality (member of the UK NEQAS consortium) and Weqas.
- 26 July 2020
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 57 (5) , 382-388
The impact of the analytical performance specifications of calcium and albumin on adjusted calcium
Aim: The generation of accurate, comparable results from traceable measurement procedures is a primary goal in harmonization efforts. In this study, the analytical performance of routine methods for calcium and albumin measurement is assessed to define the impact of the analytical bias of calcium and albumin on adjusted calcium equation performance and on reference intervals. Method: In collaboration with the Wales External Quality Assurance Scheme, six months’ worth of anonymized data that cover a concentration range of clinical interest were collected. The data were grouped by analytical platforms/methods. Results: Albumin BCG methods are positively biased (8%) to BCP methods. The overall bias for BCP methods ranges from 5.1 to –4.3% and the overall bias for BCG methods is from 2 to –6.7%. Bias for both methods is higher than the allowable minimal bias for albumin. Calcium concentrations for Roche Cobas CPC and NM-BAPTA, Beckman Arsenazo III, Abbott Architect Arsenazo III were within bias of 1.5 to –1%. However, Siemens calcium methods CPC and Arsenazo III appear to suffer from concentration-dependent bias ranging from +3 to –6%, which exceeds even the minimal allowable limits for calcium (1.3%). Adjusted calcium shows significant bias of 11%. Even with the exclusion of Siemens Advia, the scatter of adjusted calcium results exceeds that for total calcium. Conclusion: This study shows wider than acceptable analytical variation for albumin and calcium. This variation may contribute to overall adjusted calcium equations variation and invalidate the application of a harmonized reference interval for calcium and albumin.
- 26 July 2020
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 57 (5) , 382-388
The impact of the analytical performance specifications of calcium and albumin on adjusted calcium
Aim: The generation of accurate, comparable results from traceable measurement procedures is a primary goal in harmonization efforts. In this study, the analytical performance of routine methods for calcium and albumin measurement is assessed to define the impact of the analytical bias of calcium and albumin on adjusted calcium equation performance and on reference intervals. Method: In collaboration with the Wales External Quality Assurance Scheme, six months’ worth of anonymized data that cover a concentration range of clinical interest were collected. The data were grouped by analytical platforms/methods. Results: Albumin BCG methods are positively biased (8%) to BCP methods. The overall bias for BCP methods ranges from 5.1 to –4.3% and the overall bias for BCG methods is from 2 to –6.7%. Bias for both methods is higher than the allowable minimal bias for albumin. Calcium concentrations for Roche Cobas CPC and NM-BAPTA, Beckman Arsenazo III, Abbott Architect Arsenazo III were within bias of 1.5 to –1%. However, Siemens calcium methods CPC and Arsenazo III appear to suffer from concentration-dependent bias ranging from +3 to –6%, which exceeds even the minimal allowable limits for calcium (1.3%). Adjusted calcium shows significant bias of 11%. Even with the exclusion of Siemens Advia, the scatter of adjusted calcium results exceeds that for total calcium. Conclusion: This study shows wider than acceptable analytical variation for albumin and calcium. This variation may contribute to overall adjusted calcium equations variation and invalidate the application of a harmonized reference interval for calcium and albumin.
- 28 September 2016
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 54 (4) , 501-503
Assessment of a semi-quantitative screening method for diagnosis of ethylene glycol poisoning
Background: Ethylene glycol poisoning remains a rare but important presentation to acute toxicology units. Guidelines recommended that ethylene glycol should be available as an ‘urgent’ test within 4 h, but these are difficult to deliver in practice. This study assessed a semi-quantitative enzymatic spectrophotometric assay for ethylene glycol compatible with automated platforms. Methods: The ethylene glycol method was assessed in 21 samples from patients with an increased anion gap and metabolic acidosis not due to ethylene glycol ingestion, and seven samples known to contain ethylene glycol. All samples were analysed in random order in a blinded manner to their origin on a laboratory spectrophotometer. Results: In this study, seven samples were known to contain ethylene glycol at concentrations >100 mg/L. The method correctly identified all seven samples as containing ethylene glycol. No false-positives were observed. Thirteen samples gave clear negative results. Ethylene glycol was present at <20 mg/L in one sample, but this sample remained within the limits of the negative control. Passing-Bablock correlation of estimates of ethylene glycol concentration against results obtained when the samples had been analysed using the quantitative method on an automated analyser showed a good correlation (R = 0.84) but with an apparent under-recovery. Conclusions: A semi-quantitative assay for ethylene glycol was able to discriminate well between samples containing ethylene glycol and those with other causes of acidosis. It is a practical small-scale assay for rapid identification of cases of ethylene glycol poisoning.
- 28 September 2016
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 54 (4) , 501-503
Assessment of a semi-quantitative screening method for diagnosis of ethylene glycol poisoning
Background: Ethylene glycol poisoning remains a rare but important presentation to acute toxicology units. Guidelines recommended that ethylene glycol should be available as an ‘urgent’ test within 4 h, but these are difficult to deliver in practice. This study assessed a semi-quantitative enzymatic spectrophotometric assay for ethylene glycol compatible with automated platforms. Methods: The ethylene glycol method was assessed in 21 samples from patients with an increased anion gap and metabolic acidosis not due to ethylene glycol ingestion, and seven samples known to contain ethylene glycol. All samples were analysed in random order in a blinded manner to their origin on a laboratory spectrophotometer. Results: In this study, seven samples were known to contain ethylene glycol at concentrations >100 mg/L. The method correctly identified all seven samples as containing ethylene glycol. No false-positives were observed. Thirteen samples gave clear negative results. Ethylene glycol was present at <20 mg/L in one sample, but this sample remained within the limits of the negative control. Passing-Bablock correlation of estimates of ethylene glycol concentration against results obtained when the samples had been analysed using the quantitative method on an automated analyser showed a good correlation (R = 0.84) but with an apparent under-recovery. Conclusions: A semi-quantitative assay for ethylene glycol was able to discriminate well between samples containing ethylene glycol and those with other causes of acidosis. It is a practical small-scale assay for rapid identification of cases of ethylene glycol poisoning.
- Open Access
- 1 June 1990
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 265 (18) , 10604-10610
A chloride- and calcium-dependent glutamate-binding protein from rat brain. Identification as a ubiquitous constituent of the inner mitochondrial membrane.
- 1 June 1990
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 265 (18) , 10604-10610
Open AccessA chloride- and calcium-dependent glutamate-binding protein from rat brain. Identification as a ubiquitous constituent of the inner mitochondrial membrane.